Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 28, 2024
Event: Entry into a Material Definitive Agreement (Third Amendment to Credit Agreement).
Key Financial Metrics and Agreements
This filing does not report standard periodic financial metrics such as revenue, net profit, or operating cash flow. Instead, it details specific financial adjustments related to debt covenants and government credits:
- Credit Agreement Amendment: Modified the definition of Consolidated EBITDA to exclude specific costs from the standard 10% cap on non-recurring expense add-backs.
- Employee Retention Credit (ERC):
- Cash received in Q1 2024: $3.1 million.
- Expected additional cash in fiscal 2024: $3.1 million.
- Expected aggregate commission fee: Approximately $1 million.
- Escheatment Audit: Reserves and expenses related to finalizing an audit with the State of Delaware are estimated at approximately $600,000, expected to be paid in Q2 2024.
- Amendment Costs: No fees or expenses required for the amendment, other than reimbursable attorney costs.
Material Changes Versus Prior Period
The filing does not provide comparative financial performance data (e.g., year-over-year revenue or profit changes). The material change reported is the modification of the Credit Agreement dated December 22, 2020. Specifically, the amendment allows the Company to increase Consolidated EBITDA by the amount of the ERC commission fee and the Delaware escheatment audit expenses, notwithstanding the previous 10% cap on such adjustments.
Guidance, Outlook, and Risks
Outlook and Expectations:
- The Company expects to receive an additional $3.1 million in ERC cash payments during fiscal year 2024.
- The Company anticipates incurring approximately $1 million in commission fees related to these credits.
- The Company expects to pay approximately $600,000 in Q2 2024 to finalize the Delaware escheatment audit.
Risks and Contingencies:
- The filing references the full text of the Third Amendment for complete terms, noting that the summary is not exhaustive.
- Compliance with the Credit Agreement's EBITDA definitions is contingent on the successful receipt and accounting of the specified credits and audit resolutions.
Important Facts for Investor Verification
- Verify the impact of the $1 million ERC commission fee and $600,000 audit expense on the Company's debt covenant compliance ratios.
- Confirm the timing of the expected $3.1 million additional ERC cash receipt in fiscal 2024.
- Review the full text of the Third Amendment to the Credit Agreement (Exhibit 10.1) for any other modified covenants or definitions.
- Monitor the resolution of the Delaware escheatment audit to ensure the $600,000 estimate remains accurate.